Latest news with #JustineTelliez
Business Insider
25-05-2025
- Business
- Business Insider
Innate Pharma SA (IPHYF) Receives a Hold from Kepler Capital
In a report released on May 23, Justine Telliez from Kepler Capital maintained a Hold rating on Innate Pharma SA (IPHYF – Research Report), with a price target of €3.10. The company's shares closed last Friday at $1.45. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Telliez is an analyst with an average return of -8.3% and a 37.36% success rate. Telliez covers the Healthcare sector, focusing on stocks such as Genfit, Adocia SA, and Innate Pharma SA. The word on The Street in general, suggests a Hold analyst consensus rating for Innate Pharma SA with a $3.52 average price target.
Business Insider
15-05-2025
- Business
- Business Insider
Analysts Offer Insights on Healthcare Companies: Alcon (ALC) and Innate Pharma SA (OtherIPHYF)
Analysts fell to the sidelines weighing in on Alcon (ALC – Research Report) and Innate Pharma SA (IPHYF – Research Report) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks. Confident Investing Starts Here: Alcon (ALC) Kepler Capital analyst Maja Pataki maintained a Hold rating on Alcon on May 13 and set a price target of CHF88.00. The company's shares closed last Wednesday at $87.24. According to Pataki has 0 stars on 0-5 stars ranking scale with an average return of -13.6% and a 33.6% success rate. Pataki covers the Healthcare sector, focusing on stocks such as Tecan Group AG, Demant, and Qiagen. Currently, the analyst consensus on Alcon is a Strong Buy with an average price target of $110.11. Innate Pharma SA (IPHYF) Kepler Capital analyst Justine Telliez maintained a Hold rating on Innate Pharma SA on May 13 and set a price target of EUR3.10. The company's shares closed last Friday at $1.45, close to its 52-week low of $1.28.
Business Insider
26-04-2025
- Business
- Business Insider
Kepler Capital Reaffirms Their Hold Rating on Ipsen (0MH6)
Kepler Capital analyst Justine Telliez maintained a Hold rating on Ipsen (0MH6 – Research Report) on April 24 and set a price target of €120.00. The company's shares closed last Thursday at €98.35. Stay Ahead of the Market: Discover outperforming stocks and invest smarter with Top Smart Score Stocks. Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener. Telliez covers the Healthcare sector, focusing on stocks such as Genfit, Adocia SA, and Innate Pharma SA. According to TipRanks, Telliez has an average return of -9.6% and a 38.20% success rate on recommended stocks. In addition to Kepler Capital , Ipsen also received a Hold from Barclays's Charles Pitman CFA in a report issued on April 22. However, on the same day, Morgan Stanley maintained a Sell rating on Ipsen (LSE: 0MH6). Based on Ipsen's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €1.82 billion and a net profit of €113.9 million. In comparison, last year the company earned a revenue of €1.59 billion and had a net profit of €449.2 million
